Remedi is Redefining DMT Delivery
N,N-dimethyltryptamine (DMT) is a unique, tolerance-free neuroplastogen. However, oral administration can be unpredictable and fraught with adverse effects. DMT in clinical development largely requires non-oral forms of administration, which can limit access and scalability.
We have paired DMT with a best-in-class, superselective monoamine oxidase A inhibitor, or RIMA. We are developing novel formulations and kits to make DMT delivery convenient and predictable for a wide array of neuropsychiatric indications.
Get in Touch
We’re open to discussing partners and collaborations in all forms.